Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-28T14:00:20.219Z Has data issue: false hasContentIssue false

Management of extensive squamous cell carcinoma on the site of radiation-induced dermatitis with severe fibrosis: a case report

Published online by Cambridge University Press:  07 July 2010

Chirag B. Patel
Affiliation:
University of Texas Health Science Center at Houston Medical School, Houston, Texas, USA
Rashid M. Rashid
Affiliation:
Department of Dermatology, MD Anderson Cancer Center, UT-Houston, Texas, USA
Tri H. Nguyen
Affiliation:
Department of Dermatology, MD Anderson Cancer Center, UT-Houston, Texas, USA

Abstract

Dermatitis is a common side effect of radiation therapy (RT) whereas squamous cell carcinoma (SCC) is not. Management must include treatment options outside of RT, especially when cases are limited by extreme fibrosis. Here, we present a case in which a patient developed multiple SCC, severe radiation fibrosis, and limited neck mobility. This situation of increased risk for intubation required interdisciplinary coordination for proper therapeutic intervention, namely Mohs micrographic surgery to manage cutaneous lesions.

Type
Case Report
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Aubin, F, Puzenat, E, Arveux, P, Louvat, P, Quencez, E, Humbert, P. Genital squamous cell carcinoma in men treated by photochemotherapy. A cancer registry-based study from 1978 to 1998. Br J Dermatol 2001; 144: 12041206.Google Scholar
2.Hymes, DR, Strom, EA, Fife, C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006; 54: 2846.Google Scholar
3.Wagamon, K, Li, LJ. Recurrent invasive basal cell carcinoma after radiation and imiquimod: a case report. Dermatol Surg 2007; 33: 117119.Google ScholarPubMed
4.Lichter, MD, Karagas, MR, Mott, LA, Spencer, SK, Stukel, TA, Greenberg, ER. Therapeutic ionizing radiation and the incidence of BCC and SCC. The New Hampshire Skin Cancer Study Group. Arch Dermatol 2000; 136: 10071011.CrossRefGoogle ScholarPubMed
5.Karagas, MR, McDonald, JA, Greenberg, ER, Stukel, TA, Weiss, JE, Baron, JA, Stevens, MM. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst 1996; 88: 18481853.Google Scholar
6.Davis, MM, Hanke, CW, Zollinger, TW, Montebello, JF, Hornback, NB, Norins, AL. Skin cancer in patients with chronic radiation dermatitis. J Am Acad Dermatol 1989; 20: 608616.CrossRefGoogle ScholarPubMed
7.Bonner, JA, Harari, PM, Giralt, J, Azarnia, N, Shin, DM, Cohen, RB, Jones, CU, Sur, R, Raben, D, Jassem, J, Ove, R, Kies, MS, Baselga, J, Youssoufian, H, Amellal, N, Rowinsky, EK, Ang, KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567578.Google Scholar
8.Bölke, E, Gerber, PA, Lammering, G, Peiper, M, Müller-Homey, A, Pape, H, Giro, C, Matuschek, C, Bruch-Gerharz, D, Hoffmann, TK, Gripp, S, Homey, B, Budach, W. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008; 184: 105110.CrossRefGoogle ScholarPubMed
9.Milano, MT, Vokes, EE, Kao, J, Jackson, W, List, MA, Stenson, KM, Witt, ME, Dekker, A, MacCracken, E, Garofalo, MC, Chmura, SJ, Weichselbaum, RR, Haraf, DJ. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol 2006; 28: 11411151.Google Scholar
10.Mosterd, K, Krekels, GA, Nieman, FH, Ostertag, JU, Essers, BA, Dirksen, CD, Steijlen, PM, Vermeulen, A, Neumann, H, Kelleners-Smeets, NW. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol 2008; 9: 11491156.Google Scholar